The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015). This program consists of four components: (1) CME Internet Symposium: EASL 2015 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) CME Internet Symposium: European Perspective on EASL 2015: a 1-hour Internet symposium featuring Europe-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in the EU; (3) Rapid-Fire Review of EASL 2015: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference to Clinic: Reviewing and Applying Data from EASL 2015: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.
From Conference to Clinic: Reviewing and Applying Data From EASL 2015 is an interactive, case-based dinner program series designed to highlight and discuss the relative merits and clinical significance of new findings in HCV medicine presented at EASL 2015. Since the focus of the dinner programs will be on case studies and applying the data presented at EASL 2015 in a clinical setting, prior to attending a dinner program participants will be asked to view the CME Internet Symposium: EASL 2015 Review, which will familiarize them with the EASL 2015 data and serve as a comprehensive conference overview and summary. As a result of this blended learning approach, participants will gain an increased understanding of key data presented at EASL 2015 and be better prepared to address their HCV patients’ health needs and provide optimal care in a clinical setting.
All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2015 and it is not sanctioned by the organizers of EASL 2015.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
After completing this activity, the participant should be better able to:
| Nezam H. Afdhal, MD Professor of Medicine Harvard School of Medicine Chief of Hepatology, Director of Liver Center Beth Israel Deaconess Medical Center Boston, Massachusetts |
Maurizio Bonacini, MD Director, HIV-Liver Clinic Department of Transplantation California Pacific Medical Center San Francisco, California |
|
Lennox Jeffers, MD Chief of Hepatology Miami VA Medical Center Associate Chief Center for Liver Disease Professor of Medicine University of Miami’s School of Medicine Miami, Florida |
Richard A. Manch, MD, FACP, FACG Chief of Hepatology St. Joseph’s Hospital and Medical Center Clinical Professor of Medicine Creighton University School of Medicine – Phoenix Regional Campus Phoenix, Arizona |
|
Sammy Saab, MD Professor of Medicine and Surgery The Pfleger Liver Institute David Geffen School of Medicine University of California, Los Angeles Los Angeles, California |
Mark Sulkowski, MD Professor of Medicine and Medical Director Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland |
|
John M. Vierling, MD Professor of Medicine Professor of Surgery Chief of Hepatology Director of Advanced Liver Therapies St. Luke’s HospitalDirector of Baylor Liver Health Houston, Texas |
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exce ptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then pro vide that information to the supporting pharmaceutical companies to the best of our ability.
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
